According to The Insight Partners’ research, the global dPCR and qPCR market was valued at US$ 3,255.5 million in 2017 and is speculated to hit US$ 6,371.6 million by 2025 to expand at an annual growth rate of 9.1 % during 2018–2025. Increasing cases of genetic disorders, investments and funds for gene synthesis, and technological advancements in PCR technologies are the critical factors contributing to the market expansion.

A genetic mutation is a sudden change in single or multiple genes causing a dysfunction called genetic disorder. According to the National Organization’s statistics on genetic conditions and birth defects, there exist 15,500 recognized genetic disorders. As per the Genetic Disorders UK, one in twenty-five children is prone to a genetic disorder. Therefore, around 30,000 infants are newly diagnosed in the UK every year. Also, approximately 1% of people in the US are vulnerable to develop disorder D genetic condition at least once in a lifetime.

Genetic synthesis practices are receiving financial assistance from governments and medical organizations worldwide. It consists of polymerase chain reaction (PCR), a test to detect genetic material from a specific organism. In April 2018, DNA Script Organization received funds worth US$ 5.5 million from European Commission and French Investment Bank. The Zymergen Organization, in 2015, received US$ 44 million in funds from various investors such as Transcript, AME Cloud Ventures, Data Collective, Innovation Endeavors, and others. In March 2018, Synbicite UK received US$ 17.6 million in grants and US$ 318.5 million as a private investment, respectively.

The PCR technology sector is dawning in global healthcare and analytics due to relevant technological advancements. The research takes place in molecular biology labs to amplify DNA stretches, genotyping, cloning, etc. The advanced digital and real-time PCR techniques are used to diagnose diseases, identify the carrier pathogens, and aid in forensic investigations. In July 2016, researchers at Microsoft and University of Washington (UW) successfully stored 200 MB of data on synthetic DNA strands. All these parameters together catalyze the global dPCR and qPCR market.

On the contrary, the high cost of PCR systems and technical limitations associated with qPCR impede the growth of global dPCR and qPCR market.